The effect of atypical antipsychotics on hormonal and biochemical parameters in patients with schizophrenia

Abstract

Objective of this research is to study the effect of atypical antipsychotics on hormonal and biochemical parameters in patients with schizophrenia.

Materials and methods. A comprehensive clinical, psychopathological and laboratory examination of 96 patients with schizophrenia (F20 according to ICD-10) who were hospitalized in the Department of Endogenous Disorders of the Scientific Research Institute of Mental Health of the Tomsk Scientific Research Center and received second-generation antipsychotics, was carried out. The Positive and Negative Syndromes (PANSS) scale (in the adapted Russian version of SCI-PANSS) was filled for a psychometric assessment of the severity and dynamics of schizophrenia symptoms in all patients upon admission to hospital and at discharge after 4 weeks. The laboratory study included determination of the concentration of total cholesterol (TC), triglycerides (TG), high density lipoproteins (HDL), glucose, insulin and cortisol in blood serum with the calculation of lipoproteins with low (LDL) and very low (VLDL) density, atherogenic index (IA) ) and insulin resistance (HOMA-IR). Statistical data processing was performed using the standard application package SPSS Statistic (V. 17.) for Windows. Differences were considered statistically significant at p ≤0.05.

Results. The pronounced effect of four-week treatment with atypical antipsychotics on the metabolism of glucose [glucose (p <0.001) and HOMA-IR (p=0.036)] was established. A statistically significant increase in TC (p=0.005), TG (p <0.001), VLDL (p <0.001), IA (p <0.001) and TG/HDL (p <0.001) after four weeks of treatment with atypical antipsychotics. No statistically significant changes in hormone levels were established.

Conclusions. The results demonstrate the pronounced effect of a four-week treatment with atypical antipsychotics on glucose metabolism, a change in glucose level and insulin resistance index. A typical atherogenic change in the serum lipid spectrum is shown. These indicators are laboratory markers of the risk of cardiovascular disease and diabetes, and therefore careful monitoring of metabolic disorders in patients with schizophrenia is necessary.

Keywords

schizophrenia / antipsychotics / carbohydrate metabolism / lipid metabolism / hormones / metabolic disorders

References

[1] Мосолов С.Н., Рывкин П.В., Сердитов О.В. и др. Метаболические побочные эффекты современной антипсихотической фармакотерапии. Социал. и клин. психиатрия. 2008; 18 (3): 75–90. [Mosolov S.N., Ryvkin P.V., Serditov O.V. et al. Metabolicheskie pobochnye ehffekty sovremennoy antipsikhoticheskoy farmakoterapii. Sotsialʹnaya i klinicheskaya psikhiatriya. 2008; 18 (3): 75–90. (In Russ.)]

[2] Корнетова Е.Г., Меднова И.А., Дубровская В.В. и др. Метаболический синдром у больных шизофренией в психиатрической практике. Пособие для врачей. Томск: Томский гос. ун-т систем управления и радиоэлектроники. 2018; 32 c. [Kornetova E.G., Mednova I.A., Dubrovskaya V.V. et al. Metabolicheskiy sindrom u bolʹnykh shizofreniey v psikhiatricheskoy praktike. Posobie dlya vrachey. Tomsk: Tomskij gosudarstvennyj universitet sistem upravleniya i radioelektroniki . 2018; 32 p. (In Russ.)]

[3] Дубровская В.В., Корнетова Е.Г., Семке А.В. и др. Клиническая динамика и социальная адаптация у пациентов с шизофренией и сопутствующим метаболическим синдромом. Соврем. терап. психич. расстройств. 2019; (2): 17–21. [Dubrovskaya V.V., Kornetova E.G., Semke A.V. et al. Klinicheskaya dinamika i sotsialʹnaya adaptatsiya u patsientov s shizofreniey i soputstvuyushchim metabolicheskim sindromom. Sovremennaya terapiya psikhicheskikh rasstroystv. 2019; (2): 17–21. (In Russ.)] DOI: 10.21265/PSYPH.2019.24.20.003/

[4] Bode´n R., Edman G., Reutfors J. et al. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr. Dis. Treat. 2013; 9: 371–377. DOI: 10.2147/NDT.S40554.

[5] Mitchell A.J., Delaffon V., Vancampfort D. et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med. 2012; 42 (1): 125–147. DOI: 10.1017/S003329171100105X.

[6] Boiko A.S., Mednova I.A., Kornetova E.G. et al. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon. 2019; 5 (Issue 7): e02033. DOI: 10.1016/j.heliyon.2019.e02033.

[7] Горобец Л.Н., Буланов В.С., Литвинов А.В., Литвинова Т.А. Оценка биохимических факторов риска развития метаболических нарушений у больных с первым психотическим эпизодом в процессе терапии оланзапином. Социал. и клин. психиатрия. 2017; 27 (4): 10–11. [Gorobets L.N., Bulanov V.S., Litvinov A.V., Litvinova T.A. Otsenka biokhimicheskikh faktorov riska razvitiya metabolicheskikh narusheniy u bolʹnykh s pervym psikhoticheskim ehpizodom v protsesse terapii olanzapinom. Sotsialʹnaya i klinicheskaya psikhiatriya. 2017; 27 (4): 10–11. (In Russ.)]

[8] Shin H.G., Kim Y.K., Kim Y.H. et al. The relationship between the triglyceride to high-density lipoprotein cholesterol ratio and metabolic syndrome. Korean J. Family Med. 2017; 38 (6): 352–357. DOI: 10.4082/kjfm.2017.38.6.352.

[9] Von Bibra H., Saha S., Hapfelmeier A. et al. Impact of the triglyceride/high-density lipoprotein cholesterol ratio and the hypertriglyceremic-waist phenotype to predict the metabolic syndrome and insulin resistance. Horm. Metab. Res. 2017; 49 (07): 542–549. DOI: 10.1055/s-0043-107782.

[10] Salazar M.R., Carbajal H.A., Espeche W.G. et al. Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular disease in hypertensive subjects. J. Am. Society of Hypertension. 2014; 8 (10): 724–731. DOI: 10.1016/j.jash.2014.08.002.

[11] Kay S.R., Opler L.A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987; 13 (2): 261–276. DOI: 10.1093/schbul/13.2.261.

[12] Мосолов С.Н. Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. М: Новый цвет. 2001; 238 с. [Mosolov S.N. Shkaly psikhometricheskoy otsenki simptomatiki shizofrenii i kontseptsiya pozitivnykh i negativnykh rasstroystv. Мoscow: Novyj cvet. 2001; 238 р. (In Russ.)]

[13] Барденштейн Л.М., Мкртумян А.М., Алёшкина Г.А. Состояние углеводного и липидного обмена у больных параноидной шизофренией при терапии атипичными антипсихотическими препаратами. Сахарный диабет. 2010; 2: 42–44. [Bardenshtein L.M., Mkrtumyan A.M., Aleshkina G.A. The state of carbohydrate and lipid metabolism in patients with paranoid schizophrenia during therapy with atypical antipsychotics. Sakharnyi Diabet. 2010; 2: 42–44. (In Russ.)]

[14] Vancampfort D., Wampers M., Mitchell A.J. et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013; 12 (3): 240–250. DOI: 10.1002/wps.20069.

[15] Girgis R.R., Javitch J.A., Lieberman J.A. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol. Psychiatry. 2008; 13 (10): 918–929. DOI: 10.1038/mp.2008.40.

[16] Stip E., Lungu O.V., Anselmo K. et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl. Psychiatry. 2012; 2: e128. DOI: 10.1038/tp.2012.53.

[17] Scaini G., Quevedo J., Velligan D. et al. Second generation antipsychotic-induced mitochondrial alterations: implications for increased risk of metabolic syndrome in patients with schizophrenia. Eur. Neuropsychopharmacol. 2018; 28 (3): 369–380. DOI: 10.1016/j.euroneuro.2018.01.004.

RIGHTS & PERMISSIONS

Mednova I.A., Boiko A.S., Kornetova E.G., Ivanova S.A.